動脈血栓症:治療薬開発パイプライン分析

Global Markets Directが発行した調査報告書(GMDHC9676IDB)
◆英語タイトル:Arterial Thrombosis - Pipeline Review, H2 2017
◆商品コード:GMDHC9676IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2017年9月12日
◆ページ数:47
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥212,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥636,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における動脈血栓症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・動脈血栓症の概要
・動脈血栓症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・動脈血栓症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・動脈血栓症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・動脈血栓症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Arterial Thrombosis – Pipeline Review, H2 2017

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Arterial Thrombosis – Pipeline Review, H2 2017, provides an overview of the Arterial Thrombosis (Cardiovascular) pipeline landscape.

Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, arterial thrombosis can cause several serious conditions, including stroke, heart attack and peripheral arterial disease (PAD). Predisposing factors include smoking, obesity, diabetes, hypertension and high cholesterol level. Treatment includes thrombolytic agents and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Arterial Thrombosis – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 8 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively.

Arterial Thrombosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Arterial Thrombosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Arterial Thrombosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Arterial Thrombosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Arterial Thrombosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Arterial Thrombosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Arterial Thrombosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Arterial Thrombosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Arterial Thrombosis – Overview
Arterial Thrombosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Arterial Thrombosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Arterial Thrombosis – Companies Involved in Therapeutics Development
Astellas Pharma Inc
Bayer AG
Bristol-Myers Squibb Company
Eisai Co Ltd
Johnson & Johnson
Sanofi
Thromboserin Ltd
Arterial Thrombosis – Drug Profiles
AB-002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-1468240 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6537 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-654457 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-884775 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986120 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-3 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-110 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-5539 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ER-410660 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-9375 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OA-150 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PZ-128 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-007867 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-216471 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THL-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Arterial Thrombosis – Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Arterial Thrombosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Arterial Thrombosis - Pipeline by Astellas Pharma Inc, H2 2017
Arterial Thrombosis - Pipeline by Bayer AG, H2 2017
Arterial Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2017
Arterial Thrombosis - Pipeline by Eisai Co Ltd, H2 2017
Arterial Thrombosis - Pipeline by Johnson & Johnson, H2 2017
Arterial Thrombosis - Pipeline by Sanofi, H2 2017
Arterial Thrombosis - Pipeline by Thromboserin Ltd, H2 2017
Arterial Thrombosis - Dormant Projects, H2 2017

List of Figures
Number of Products under Development for Arterial Thrombosis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

【レポートのキーワード】

動脈血栓症

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 動脈血栓症:治療薬開発パイプライン分析(Arterial Thrombosis - Pipeline Review, H2 2017)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆